Physician profile
Daniel C Brown
NPI 1407802267
$1,589.16
in general payments reported to CMS, 2019-2025
20 companies · $541 in 2025
The $541 reported for 2025 was more than what 80% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $64.39 · 2021: $25.91 · 2022: $159 · 2023: $223 · 2024: $387 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134 · Education: $16.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.84 |
| Education | $16.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $257.39 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $249.67 | 2022-2025 | Tezspire |
| Chiesi USA, INC. | $174.46 | 2019-2020 | |
| Alcresta Therapeutics, INC. | $171.49 | 2025 | Relizorb |
| Baxter Healthcare | $129.41 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Synclara Cough System |
| Philips North America LLC | $85.17 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Sobi, INC | $85.07 | 2019-2024 | |
| Pharming Healthcare, INC. | $79.54 | 2023-2025 | Ruconest |
| Abbvie INC. | $71.05 | 2019-2024 | |
| Harmony Biosciences LLC | $43.69 | 2024-2025 | |
| Genzyme Corporation | $38.03 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $37.86 | 2023-2024 | Trikafta |
| Amgen INC. | $31.79 | 2023-2025 | Tezspire |
| Insulet Corporation | $25.91 | 2021 | |
| Azurity Pharmaceuticals, INC. | $23.41 | 2025 | Alvesco |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $20.94 | 2024 | Smartvest |
| Glaxosmithkline, LLC. | $18.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.26 | 2022 | |
| Gilead Sciences, INC. | $14.98 | 2022 | |
| Merck Sharp & Dohme LLC | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.